Clinical Trial Update: Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating EDP-938 for respiratory syncytial virus infection in hematopoietic cell transplant recipients with upper respiratory tract infection; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• EDP-938 (EDP-938)

Snippet

Sponsor: Enanta Pharmaceuticals, Inc | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: TERMINATED | Results posted: 2024-08-22